Skip to main content

Table 1 Relation between Bcl-2 status and other clinicopathological factors in patient groups with no adjuvant therapy or tamoxifen monotherapy

From: Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy

 

No adjuvant therapy

Tamoxifen monotherapy

Factors

Bcl-2

 

P-value

Bcl-2

 

P-value

 

+ (%)

-

 

+ (%)

-

 

Menopause

  

0.0049*

  

0.1249

Post

156 (58)

112

 

191 (64)

108

 

Pre

210 (70)

92

 

117 (71)

48

 

Tumor size

 

0.0023*

 

0.0051*

>20 mm

199 (58)

143

 

178 (61)

112

 

≤20 mm

204 (70)

88

 

138 (74)

49

 

Node

 

0.9049

 

0.2938

+

96 (63)

56

 

141 (64)

80

 

-

307 (64)

175

 

175 (68)

81

 

Grade

 

<0.0001*

 

0.0040*

II + III

244 (54)

205

 

170 (61)

109

 

I

157 (86)

26

 

145 (74)

52

 

ER

 

<0.0001*

 

<0.0001*

+

330 (88)

45

 

290 (74)

100

 

-

71 (28)

186

 

26 (30)

61

 

PR

 

<0.0001*

 

<0.0001*

+

242 (89)

30

 

189 (76)

59

 

-

159 (44)

200

 

127 (55)

102

 

HER2

 

<0.0001*

 

 0.0005*

+

19 (21)

70

 

8 (33)

16

 

-

381 (70)

160

 

308 (68)

145

 

Total

634

 

477

 
  1. *Significant, P < 0.05/7 = 0.0071 (Bonferroni adjustment)
  2. Post and Pre postmenopause and premenopause at the time of diagnosis, + positive, − negative, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us